Jessica A. Pollard, MD
Clinical Director, Hematologic Malignancy Program; Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Image
Jessica A. Pollard, MD
Clinical Director, Hematologic Malignancy Program; Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
Columbia University College of Physicians and Surgeons
2000
New York
NY
Residency
Seattle Children's Hospital/University of Washington
2003
Seattle
WA
Fellowship
Fred Hutchinson Cancer Research Center
Seattle Children’s Hospital/University of Washington
2006
Seattle
WA
Professional History
Dr. Jessica Pollard joins the Hematologic Malignancies service as faculty member and clinical researcher. Dr. Pollard came to Dana-Farber after working as an attending at Seattle Children’s Hospital/Fred Hutchinson Cancer Research Center from 2006-2014. For the last 4 years she has been an attending at Maine Children’s Cancer Program at Maine Medical Center where she was an Attending Physician in the Division of Pediatric American Board of Pediatrics, Pediatric Hematology/Oncology Hematology/Oncology, and Associate Professor of Pediatrics at Tufts University School of Medicine.
Dr. Pollard received her B.S. degree, with Honors, in biology from Cornell University in 1995 and went on to earn her M.D. from Columbia University in 2000. She completed her residency in pediatrics at the University of Washington and Seattle Children’s Hospital before joining a joint pediatric hematology/oncology fellowship program with the Fred Hutchinson Cancer Research Center in 2003. Following the completion of her fellowship training, Dr. Pollard was faculty at the University of Washington and Seattle Children’s Hospital until 2014. She relocated to Maine in 2014 where she worked as an attending at Maine Children’s Cancer Program/Maine Medical Center until her relocation to Boston in 2018.
Dr. Pollard’s expertise lies in the management of children with myeloid malignancies. Her research focus is in development of clinical trials that improve outcomes in acute myeloid leukemia (AML) and related myeloid disorders by utilizing knowledge of disease biology to optimize treatment approaches. Moreover, she has an interest in germline conditions that predispose to myeloid malignancies and how such conditions impact treatment considerations.
Publications
Genetic Predisposition to Hematologic Malignancies. View Abstract
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. View Abstract
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. View Abstract
Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report. View Abstract
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. View Abstract
Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. View Abstract
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. View Abstract
Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy. View Abstract
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. View Abstract
Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. View Abstract
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. View Abstract
Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders. View Abstract
Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. View Abstract
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. View Abstract
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. View Abstract
Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. View Abstract
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. View Abstract
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. View Abstract
Morphologic remission status is limited compared to ?N flow cytometry: a Children's Oncology Group AAML0531 report. View Abstract
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium. View Abstract
Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. View Abstract
Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. View Abstract
A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. View Abstract
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. View Abstract
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. View Abstract
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. View Abstract
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. View Abstract
Improving Time to Antibiotics for Pediatric Oncology Patients With Suspected Infections: An Emergency Department-Based Quality Improvement Intervention. View Abstract
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. View Abstract
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. View Abstract
Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. View Abstract
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). View Abstract
Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. View Abstract
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. View Abstract
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. View Abstract
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. View Abstract
A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. View Abstract
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. View Abstract
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. View Abstract
First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. View Abstract
Medical management of invasive fungal infections of the central nervous system in pediatric cancer patients. View Abstract
The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia. View Abstract
Molecular therapeutic approaches for pediatric acute myeloid leukemia. View Abstract
The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. View Abstract
High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. View Abstract
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. View Abstract
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. View Abstract
Pure erythroid leukemia following precursor B-cell lymphoblastic leukemia. View Abstract
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. View Abstract
The role of competition in word learning via referent selection. View Abstract
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. View Abstract
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. View Abstract
Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. View Abstract
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. View Abstract
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. View Abstract